**Pharmaceutical Products:** approx. 60%
**Medical Devices:** approx. 25%
**Cosmetic Products:** approx. 15%

**TOP 3 Markets:**

1. **China:** approx. 70%
2. **USA:** approx. 15%
3. **Europe:** approx. 10%

Huadong Medicine Co., Ltd generates the majority of its revenue from the sale of pharmaceutical products, followed by medical devices and cosmetic products. The Chinese market is the largest revenue contributor, attributed to strong local presence and demand for pharmaceutical products. The USA and Europe are also significant markets served through strategic partnerships and product exports.

**Production Sites:** Mainly in China

Huadong Medicine Co., Ltd mainly produces its products in China. The company operates several production facilities in the country that focus on the manufacturing of pharmaceutical products and medical devices. These sites are strategically located in various regions of China to maximize efficiency in production and logistics.

In addition, Huadong Medicine invests in research and development to continuously expand its production capacity and product range. The company may also enter into international partnerships or joint ventures to strengthen its global presence.

**Focus on Biopharmaceuticals and Innovative Medicines:**

Huadong Medicine Co., Ltd has increased its investment in the research and development of biopharmaceuticals in recent years. The company aims to expand its product pipeline through innovative medicines, particularly in the fields of oncology and immunology.

**International Expansion:**

Another strategic focus is on international expansion. Huadong Medicine has intensified partnerships and acquisitions abroad to expand its global presence and tap into new markets.

**Digital Transformation:**

The company is focusing on digitizing its business processes to achieve efficiency gains and enhance customer experience. This includes investments in modern technologies and expanding digital platforms.

These strategic initiatives are intended to help Huadong Medicine strengthen its market position and ensure sustainable growth in the years to come.

**Imported Raw Materials:** Pharmaceutical active ingredients, packaging materials

**Main Import Countries:** Germany, USA, India

Huadong Medicine Co., Ltd imports a variety of raw materials necessary for the production of their pharmaceutical products. This includes pharmaceutical active ingredients, which are often sourced from countries with advanced pharmaceutical industries such as Germany and the USA. These countries offer high-quality active ingredients that meet strict regulatory requirements.

In addition, packaging materials are imported to pack the products safely and efficiently. India is also a significant supplier, especially for generic pharmaceutical active ingredients, as the country has a strong generic drug industry.

This import strategy enables Huadong Medicine to produce high-quality products while optimizing costs by sourcing from different countries.

**Market share in China:** 8% (2024, estimated)
**Research & Development (R&D) expenses:** 1.2 billion CNY (2024)
**Gross margin:** 35% (2024)

Huadong Medicine Co., Ltd has a significant competitive advantage in the Chinese pharmaceutical industry, particularly due to its strong market share of approximately 8%. This positions the company as one of the leading players in one of the largest pharmaceutical markets in the world.

Another crucial factor is the substantial investment in research and development, which amounted to about 1.2 billion CNY in 2024. These investments enable the company to develop innovative products and continuously expand its product pipeline, contributing to a sustainable competitive advantage in the long term.

The gross margin of 35% indicates that Huadong Medicine is able to sell its products with a healthy profit margin, reflecting efficient production processes and strong pricing strategies. This financial stability allows the company to continue investing in growth and innovation.

**Institutional Investor Share:** approximately 35% (estimated for 2025)
**Insider Buys/Sells:** No significant transactions in the last year (estimated for 2025)

The institutional investor share in Huadong Medicine Co., Ltd is estimated to be around 35%. This indicates that a significant portion of the shares is held by professional investors, which may suggest confidence in the company's long-term development.

There were no significant insider buys or sells in the last year, indicating that the management and other insiders are currently not making significant changes to their stake in the company. This could be seen as a sign that they are satisfied with the current company strategy and development.

**Market share of Huadong Medicine Co., Ltd:** Estimated 4% (2025)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd:** 15%
2. **Shanghai Pharmaceuticals Holding Co., Ltd:** 10%
3. **CSPC Pharmaceutical Group Limited:** 8%
4. **China Resources Pharmaceutical Group Limited:** 7%
5. **Hengrui Medicine Co., Ltd:** 6%
6. **Huadong Medicine Co., Ltd:** 4%
7. **Fosun Pharma:** 3%
8. **Yunnan Baiyao Group Co., Ltd:** 2%
9. **Tasly Pharmaceutical Group Co., Ltd:** 2%
10. **Tong Ren Tang Technologies Co., Ltd:** 1.5%

Huadong Medicine Co., Ltd has a moderate market share of around 4% compared to its largest competitors. The market share indicates that the company has some influence in the market, but is not among the dominant players.

Huadong Medicine's economic moat is less pronounced compared to leading companies like Sinopharm and Shanghai Pharmaceuticals. These companies have significant competitive advantages due to their size, extensive distribution networks, and wide product portfolios. However, Huadong Medicine could have a certain advantage through specialized products or niche markets, although not as strong as that of the industry leaders.

Overall, Huadong Medicine's economic moat is limited compared to the leading companies, meaning they operate in a competitive environment where larger players with stronger resources and networks dominate.

**Revenue Growth:** 8.5% (2024)
**R&D Expenses:** 12% of revenue (2024)
**Market Share in China:** 5% (2024)

Huadong Medicine Co., Ltd recorded a revenue growth of 8.5% in 2024, indicating solid demand for their products and an effective distribution strategy. The company is heavily investing in research and development, with 12% of revenue allocated to this area. This demonstrates a clear commitment to innovation and the development of new products, which could lead to a stronger market position in the long term.

The 5% market share in China is significant, considering that the Chinese pharmaceutical market is one of the largest and fastest-growing markets globally. This position could help Huadong Medicine Co., Ltd benefit from the increasing demand for healthcare products in the region.

In summary, Huadong Medicine Co., Ltd is well positioned for future success through its growth strategy and investments in research and development. This could make the stock an attractive investment, especially for investors interested in long-term growth.

**Dividend Yield:** 2.5% (2025, estimated)
**Dividend History:** Continuous payout over the last 5 years

Huadong Medicine Co., Ltd has regularly distributed dividends to its shareholders in recent years. The dividend yield is estimated to be around 2.5% for the year 2025, based on the latest available financial data and the company's past payout policy.

The company has a solid balance sheet and demonstrates a reliable dividend policy, indicating its commitment to providing shareholders with continuous returns in the future as well. The stability of dividend payments is supported by Huadong Medicine's strong market position and sustainable business model.